Steve Miller, CMO, discusses his thoughts on the recently approved gene therapy for acute lymphoblastic leukemia, the accompanying price tag of said therapy, and the challenges the health care system faces paying for gene therapies and making them accessible to patients.

Conferences

Improving provider response to adverse events through an algorithm.

News

The 70-gene signature assay for early breast cancer provides physicians with actionable information and may be associated with adjuvant therapy decisions.

Patients with metastatic cancer who are treated with an anti-programmed death (PD-1) therapy are at an increased risk for neurological complications, according to a study published in JAMA Neurology (October 2017;74[10]:1216-1222).

Read More

A recent phase III trial demonstrated that initial therapy with an immuno-agent improves progression-free survival (PFS) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer, published in the Journal of Clinical Oncology (online October 2, 2017; doi:10.1200/JCO.2

Read More

Many patients with stage IV metastatic cancer achieve stable disease after treatment with radiation therapy and immunotherapy.

Research in Review

Scientists said on Monday they had pinpointed a particular type of immune system cell that could predict more precisely if cancer patients are likely to respond to modern immunotherapy medicines.

In a recent trial, researchers determined complete response rates in patients with aggressive B-cell lymphomas after treatment with new a CAR T-cell product.

-----

Related Content

Read More

Chimeric antigen receptor (CAR) T-cells may elicit responses in solid cancers by inducing cancer cell death and the release of tumor antigens that could stimulate T-cell activity, according to research presented at the 2017 ASCO Annual Meeting (June 2-6, 2017; Chicago, IL).

-----

Related Content

Read More

Early activation of programmed cell death-1 (PD-1) in CD8 T-cells after immunotherapy treatment is crucial to anti-tumor response for patients with non-small cell lung cancer (NSCLC), according to research published in Proceedings of the National Academy of Sciences (published online April 26, 2017; doi:10.1073/pnas.1705327114).

-----

Read More

Subscribe to Immuno-Oncology